RxDoctor Payments Data

Renato de la Rosa, MD

Internal Medicine · Chula Vista, CANPI 1114966777

Payments from drug & device makers

$3,529in general payments, 2019–2025

Across 57 payments — averaging $61.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$384
  • AstraZeneca$370
  • Novo Nordisk$328
  • Abbott$284
  • Amgen$254
  • Gilead$229
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$3,47098%
  • Education$592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,529 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$127,852
Medicare patients
287
Services billed
1,097

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin239$314,223
OzempicSemaglutide81$112,382
JanuviaSitagliptin Phosphate70$77,972
EliquisApixaban64$69,232
TrulicityDulaglutide41$68,334
KerendiaFinerenone40$47,819
FarxigaDapagliflozin Propanediol17$21,266
JanumetSitagliptin Phos/Metformin Hcl26$20,941
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$20,884
EntrestoSacubitril/Valsartan23$18,693
XareltoRivaroxaban12$15,499
InvokanaCanagliflozin13$14,478
TradjentaLinagliptin25$14,300
VascepaIcosapent Ethyl15$9,528
Atorvastatin Calcium618$8,609

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$19$328,524264 claims
Novo NordiskOzempic$328$112,38281 claims
Lilly USA, LLCTrulicity$114$68,33441 claims
BayerKerendia$384$47,81940 claims
Johnson & JohnsonXarelto, Invokana$123$29,97725 claims
AstraZenecaFarxiga$370$21,26617 claims
GSKTrelegy Ellipta$76$20,88429 claims
NovartisEntresto$145$18,69323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Chula Vista

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →